| Literature DB >> 16137609 |
Milena Pitashny1, Yehuda Shoenfeld.
Abstract
Rituximab is a chimeric mouse-human monoclonal antibody, which binds to CD20, a B cell surface marker, leading to cell death by complement induced lysis and apoptosis. Since the introduction of this drug in the treatment of non-Hodgkin lymphoma, its applications have been extended to autoimmune diseases. This review summarizes the actual possible uses of this novel immune system targeted drug, and explains the mechanism of B cell depletion in autoimmune diseases.Entities:
Mesh：
Substances：
Year: 2005 PMID： 16137609 DOI： 10.1016/j.autrev.2005.03.002
Source DB: PubMed Journal: Autoimmun Rev ISSN： 1568-9972 Impact factor: 9.754